INNOCARE(688428)2025-01-16 09:46Revenue Projections - The company expects revenue from Obinutuzumab to be approximately RMB 1,001 million in 2024, representing a growth of about 49% compared to the previous year[4]. - Total operating revenue is projected to be around RMB 1,010 million, reflecting a growth of approximately 37% year-over-year[4]. - The sales revenue of Obinutuzumab has increased by about 49% due to its coverage under medical insurance for three indications, including being the first and only BTK inhibitor approved for marginal zone lymphoma in China[6]. Net Loss Estimates - The net loss attributable to the parent company is estimated at RMB 443 million, a reduction of about 30% compared to the previous year[4]. - The net loss attributable to the parent company, after deducting non-recurring gains and losses, is expected to be around RMB 444 million, a decrease of approximately 29% year-over-year[4]. Research and Development - The company has increased its R&D investment by approximately 8.4% compared to the previous year, indicating a commitment to pipeline development[6]. Financial Stability - The company incurred an unrealized exchange loss of about RMB 33 million in 2024, which is less than the unrealized exchange loss from the previous year[6]. - The sales expense ratio has continuously decreased, enhancing the company's sustainable development capabilities[6]. - The company has not identified any significant uncertainties that would affect the accuracy of this earnings forecast[7]. Data Disclosure - The data provided is preliminary and subject to change, with the final audited financial data to be disclosed in the 2024 annual report[8].